A Long-Term Safety Follow-Up Study for Patients Treated With Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007)
Latest Information Update: 25 Sep 2024
At a glance
- Drugs WU-CART-007 (Primary)
- Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors WUGEN
Most Recent Events
- 01 Sep 2022 Planned initiation date changed from 15 Aug 2022 to 15 Dec 2022.
- 01 Sep 2022 Planned initiation date (estimated date for recruitment of the first subject) changed from 15 Aug 2022 to 15 Dec 2022
- 25 Aug 2022 New trial record